8-K: Celularity Secures $10M Financing, Eyes Longevity Market

Celularity Inc. has closed a $10 million financing round, including senior secured and convertible notes, with potential for an additional $2 million, aimed at bolstering its financial position and strategic shift towards healthy aging and performance optimization.

Summary

• Celularity Inc. has secured $10.00 million in gross proceeds through a new financing round with Philip A. Barach, co-founder and former president of DoubleLine Capital LP.
• The financing includes a $7.0 million Senior Secured Non-Convertible Promissory Note and a $3.0 million Senior Secured Convertible Promissory Note (initial tranche).
• There is potential for an additional $2.0 million in funding, subject to specified closing conditions and the investor's election.
• The Senior Note accrues interest at 4% per annum, increasing to 12% upon an Event of Default, and matures on the earlier of April 30, 2026, or a significant financing event.
• The Convertible Note accrues interest at 8% per annum, payable in kind (PIK), increasing to 12% upon an Event of Default, and matures on December 31, 2026.
• The Convertible Note is convertible into Class A common stock at a price of $1.66 per share, subject to adjustment, but never less than $1.28.
• Celularity issued five-year warrants to purchase an aggregate of 3,707,657 shares of Class A Common Stock to the investor, exercisable from June 19, 2026, at $2.00 per share.
• The Senior Note is secured by a first-priority lien on substantially all of Celularity's assets, while the Convertible Note is secured by a first-priority lien on proceeds from a qualified financing.
• The investor has been granted the right to designate a non-voting observer to attend meetings of the Company's Board of Directors, with Philip A. Barach as the initial observer.
• Celularity has agreed to file registration statements with the SEC covering the resale of the shares underlying the convertible notes and warrants.
• The Company will pay its financial advisor, Odeon Capital Group LLC, a 2% cash fee of the principal amount and issue 70,000 five-year warrants at an exercise price of $2.00 per share.
• Celularity will reimburse the Initial Purchaser for up to $50,000 in reasonable legal, structuring, and due diligence fees and expenses.

Sentiment

Score: 6

Explanation: The financing provides critical capital and a strategic runway, which is positive for the company's continuity and stated shift towards the longevity market. However, the terms (secured debt, high interest rates, and significant potential dilution) indicate a costly capital raise, reflecting underlying financial pressures. The sentiment is cautiously optimistic, acknowledging the necessity and potential, but also the associated costs and risks.

Positives

• Secured $10.00 million in immediate gross proceeds, providing crucial capital for ongoing operations and strategic initiatives.
• Potential for an additional $2.0 million in funding, offering further financial flexibility.
• The financing strengthens the company's financial position and provides meaningful flexibility, as stated by the CEO.
• The company is focusing on leveraging its placental-derived platform for healthy aging and performance optimization, aligning with emerging longevity market trends.
• The investor, Philip A. Barach, is a significant financial figure, indicating a level of confidence in Celularity's future.

Negatives

• The Senior Secured Note carries a 4% annual interest rate, escalating to 12% upon an Event of Default, indicating a higher cost of capital.
• The Convertible Note has an 8% annual interest rate, payable in kind, also escalating to 12% upon an Event of Default, which can lead to further debt accumulation.
• The Senior Note is secured by a first-priority lien on substantially all of Celularity's assets, which significantly limits the company's unencumbered asset base.
• The issuance of 3,707,657 warrants and the convertibility of the notes represent significant potential dilution for existing shareholders.
• The conversion price of $1.66 per share and warrant exercise price of $2.00 per share may be at a discount to the market price, further contributing to dilution.
• The need for secured, high-interest financing suggests challenges in raising capital on more favorable terms.

Risks

• The issuance of warrants and convertible notes will result in significant dilution to existing shareholders upon exercise and conversion.
• Failure to meet the terms of the notes could trigger an Event of Default, leading to a 12% interest rate and immediate payment of the Mandatory Default Amount.
• The first-priority lien on substantially all assets for the Senior Note could restrict future financing options or asset sales.
• The company's ability to secure the additional $2.0 million is subject to conditions and the investor's election, which is not guaranteed.
• The success of the strategic shift towards longevity and age-related disease applications is uncertain and subject to market acceptance and regulatory approvals.
• The company must comply with SEC filing requirements for the resale of underlying shares, which involves ongoing costs and potential liabilities.

Future Outlook

Celularity intends to more fully articulate its corporate strategy in the new year, focusing on aligning scientific capabilities with long-term opportunities in longevity and age-related disease. The objective is to reshape the company into a durable, disciplined organization that can translate innovation into sustainable value for patients and shareholders.

Management Comments

• "This closing strengthens Celularitys financial position and provides meaningful flexibility as we continue to analyze and prioritize our platform and pipeline."
• "We appreciate Phil Barachs long-term support and confidence in Celularity as we move forward."
• "Celularity is increasingly focused on leveraging its placental-derived platform to address areas of significant unmet medical need focused on applications related to pioneering healthy aging and performance optimization."
• "Celularity believes its proprietary technologies position it to participate meaningfully in the emerging longevity landscape, while continuing to responsibly manage and prioritize its existing portfolio."
• "In the new year, we intend to more fully articulate Celularitys corporate strategy, including our plan to align our scientific capabilities with long-term opportunities in longevity and age-related disease."
• "Our objective is to reshape Celularity into a durable, disciplined organization that can translate innovation into sustainable value for patients and shareholders."

Industry Context

Celularity operates in the regenerative and cellular medicine space, specifically utilizing a placental-derived platform. The stated strategic shift towards 'healthy aging and performance optimization' positions the company within the growing longevity market, a trend attracting increasing investment and research interest in the biotech and healthcare sectors. This move suggests an adaptation to broader industry trends focusing on age-related diseases and extending human healthspan.

Corporate Governance

Related Party Transactions

• The financing transactions were conducted with Philip A. Barach, co-founder and former president of DoubleLine Capital LP, who is identified as an accredited investor. This constitutes a related party transaction.

Stakeholder Impact

• **Shareholders**: Potential for significant dilution from the conversion of notes and exercise of warrants. The secured nature of the debt could impact future equity raises or asset sales. The strategic shift could offer long-term value but carries execution risk.
• **Creditors**: The Senior Note holders benefit from a first-priority lien on substantially all company assets, enhancing their security. Convertible Note holders have a first-priority lien on proceeds from a qualified financing.
• **Management**: The financing provides necessary capital and flexibility to pursue strategic initiatives, but also imposes covenants and obligations that require careful management.
• **Employees**: The financing provides stability for ongoing operations, potentially securing jobs and supporting future R&D efforts related to the new strategic focus.

Next Steps

• More fully articulate Celularity's corporate strategy in the new year.
• Align scientific capabilities with long-term opportunities in longevity and age-related disease.
• Continue to responsibly manage and prioritize the existing portfolio.
• File registration statements with the SEC for the resale of shares underlying the convertible notes and warrants.

Key Dates

Recommendation

The financing provides a critical capital injection, offering Celularity a lifeline and runway to execute its strategic shift towards the longevity market. However, the terms are quite stringent, including high interest rates on secured debt and significant potential dilution from warrants and convertible notes. While the capital is necessary, the cost of this financing and the underlying financial pressures it addresses suggest that the company faces substantial challenges. Investors should hold to observe the execution of the new corporate strategy and assess whether the company can translate its placental-derived platform into sustainable value, mitigating the dilutive and debt-related risks.

Keywords

Celularity, Financing, Senior Secured Note, Convertible Note, Warrants, Capital Raise, Regenerative Medicine, Cellular Medicine, Longevity, Age-related Disease, SEC Filing, Dilution, Debt Financing, Equity Financing